Table 2.
Safety outcomes after CAR T-cell therapy administration.
| Adverse Event | All (%) | Grade 1–2 (%) | Grade 3–4 (%) | Grade 5 (%) |
|---|---|---|---|---|
| CRS (n = 66) | 58 (88%) | 57 (86%) | 0 (0%) | 1 (2%) |
| Age ≤ 70 (n = 52) | 46 (88%) | 45 (87%) | 0 (0%) | 1 (2%) |
| Age > 70 (n = 14) | 12 (86%) | 12 (86%) | 0 (0%) | 0 (0%) |
| ECOG 0–1 (n = 53) | 48 (91%) | 48 (91%) | 0 (0%) | 0 (0%) |
| ECOG 2–4 (n = 13) | 10 (77%) | 9 (69%) | 0 (0%) | 1 (8%) |
| ICANS (n = 66) | 37 (56%) | 20 (30%) | 17 (26%) | 0 (0%) |
| Age ≤ 70 (n = 52) | 27 (52%) | 14 (27%) | 13 (25%) | 0 (0%) |
| Age > 70 (n = 14) | 10 (71%) | 6 (43%) | 4 (29%) | 0 (0%) |
| ECOG 0–1 (n = 53) | 29 (55%) | 17 (32%) | 12 (23%) | 0 (0%) |
| ECOG 2–4 (n = 13) | 8 (62%) | 3 (23%) | 5 (50%) | 0 (0%) |
| Infection (n = 66) * | 32 (48%) | 16 (24%) | 17 (26%) | 1 (2%) |
| Age ≤ 70 (n = 52) | 21 (40%) | 12 (23%) | 11 (21%) | 0 (0%) |
| Age > 70 (n = 14) | 11 (79%) | 4 (29%) | 6 (43%) | 1 (7%) |
| ECOG 0–1 (n = 53) | 23 (43%) | 10 (19%) | 13 (25%) | 1 (2%) |
| ECOG 2–4 (n = 13) | 9 (69%) | 6 (46%) | 4 (31%) | 0 (0%) |
| CMV Viremia (n = 57) | 23 (40%) | 21 (37%) | 2 (4%) | 0 (0%) |
| Anemia (n = 66) | 66 (100%) | 21 (32%) | 45 (68%) | 0 (0%) |
| Neutropenia (n = 66) | 66 (100%) | 0 (0%) | 66 (100%) | 0 (0%) |
| Thrombocytopenia (n = 66) | 66 (100%) | 26 (39%) | 40 (61%) | 0 (0%) |
Abbreviations: CMV, cytomegalovirus; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome. * CMV viremia excluded.